Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Other Non-Current Liabilities: 2020-2024

Historic Other Non-Current Liabilities for Mereo BioPharma Group (MREO) over the last 5 years, with Dec 2024 value amounting to $821,000.

  • Mereo BioPharma Group's Other Non-Current Liabilities fell 37.31% to $652,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $652,000, marking a year-over-year decrease of 37.31%. This contributed to the annual value of $821,000 for FY2024, which is 7.46% up from last year.
  • Per Mereo BioPharma Group's latest filing, its Other Non-Current Liabilities stood at $821,000 for FY2024, which was up 7.46% from $764,000 recorded in FY2023.
  • In the past 5 years, Mereo BioPharma Group's Other Non-Current Liabilities ranged from a high of $65.2 million in FY2020 and a low of $764,000 during FY2023.
  • For the 3-year period, Mereo BioPharma Group's Other Non-Current Liabilities averaged around $818,000, with its median value being $821,000 (2024).
  • As far as peak fluctuations go, Mereo BioPharma Group's Other Non-Current Liabilities crashed by 92.27% in 2022, and later increased by 7.46% in 2024.
  • Yearly analysis of 5 years shows Mereo BioPharma Group's Other Non-Current Liabilities stood at $65.2 million in 2020, then crashed by 82.77% to $11.2 million in 2021, then crashed by 92.27% to $869,000 in 2022, then dropped by 12.08% to $764,000 in 2023, then increased by 7.46% to $821,000 in 2024.